|
Functional Therapeutics and Functional Proteins are central to PhenoCure's
technology strategy. Phenocure has a dual pronged approach to build
short and long term shareholder value. Revenues will be generated
from both Drug discovery as well as Enabling technologies. By use
of this dual approach potential returns are maximised whilst reducing
risk and undue exposure. PhenoCure's technologies are all at market
stage and are projected to generate revenue from year 1 of full
operations.
(i)
PFR* - Functional Therapeutics
A proprietary Drug Discovery and delivery Technology a superior
alternative to gene therapy
(ii)
Foldases and associated technologies* - Functional Proteins
A proprietary Protein expression Technology
*Patents pending
|
